# Nuclide record lu-177-dotatate-generic (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/lu-177-dotatate-generic/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "lu-177-dotatate-generic" ;
  schema:name "Lutetium-177 dotatate (radioligand equivalent)"@en ;
  schema:alternateName "Bexlutry"@en, "generic lutetium Lu 177 dotatate"@en, "Bexlutry" ;
  schema:description "A second, cheaper version of an already-approved radioactive drug for neuroendocrine tumours has been approved, using the same active radioactive ingredient as the original but made by a different company."@en ;
  schema:url <https://nuclide.cc/drugs/lu-177-dotatate-generic/> ;
  schema:dateModified "2026-09-27"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525>, <https://www.curiumpharma.com/2026/09/14/fda-approval-bexlutry/>, <https://www.fiercepharma.com/pharma/fda-approves-first-radioligand-equivalent-curiums-copycat-novartis-lutathera>, <https://trial.medpath.com/news/fda-approves-curium-s-bexlutry-first-generic-radioligand-challenging-lutathera-s-gep-net-monopoly> ;
  nuclide:status "approved" ;
  nuclide:tag "radioligand therapy", "generic", "neuroendocrine tumours", "beta emitter" ;
  nuclide:modality "radioligand therapy" ;
  nuclide:approval "US 2026: Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut and hindgut tumours, in adults" ;
  nuclide:related <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/prrt/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/curium/> .